Acetohexamide
<templatestyles src="Module:Hatnote/styles.css"></templatestyles>
Systematic (IUPAC) name | |
---|---|
1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamide
|
|
Clinical data | |
Trade names | Dymelor |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a602021 |
Pharmacokinetic data | |
Protein binding | 90% |
Identifiers | |
CAS Number | 968-81-0 |
ATC code | A10BB31 (WHO) |
PubChem | CID: 1989 |
IUPHAR/BPS | 6793 |
DrugBank | DB00414 |
ChemSpider | 1912 |
UNII | QGC8W08I6I |
KEGG | D00219 |
ChEBI | CHEBI:28052 |
ChEMBL | CHEMBL1589 |
Chemical data | |
Formula | C15H20N2O4S |
Molecular mass | 324.395 g/mol |
|
|
|
|
(verify) |
Acetohexamide (trade name Dymelor) is a first-generation sulfonylurea medication used to treat diabetes mellitus type 2, particularly in people whose diabetes cannot be controlled by diet alone.
Mechanism of action
Acetohexamide lowers blood sugar by stimulating the pancreas to secrete insulin and helping the body use insulin efficiently.[1] The pancreas must produce insulin for this medication to work. For this reason, acetohexamide is not used to treat diabetes mellitus type 1.
Risks
Oral hypoglycemic drugs, including acetohexamide, have been associated with increased cardiovascular mortality. Talk to your doctor about the possible risks, benefits, and alternatives of using this drug for your condition.[2]
References
- ↑ [1] - Metformin Side Effects
- ↑ Medline Plus - Acetohexamide
<templatestyles src="Asbox/styles.css"></templatestyles>